Lenograstim:更新其药理特性和使用的化疗所致嗜中性白血球减少症及相关临床设置。

文章的细节

引用

复制到剪贴板

邓恩CJ,果阿吉隆坡

Lenograstim:更新其药理特性和使用的化疗所致嗜中性白血球减少症及相关临床设置。

药。2000年3月,59 (3):681 - 717。

PubMed ID

10776839 (在PubMed

]

文摘

未标记的:Lenograstim糖化重组人粒细胞集落刺激因子的形式。药物是用来减少危及生命的感染患者的中性粒细胞减少的风险,尤其是在细胞毒性化疗。Lenograstim化疗后中性粒细胞显著复苏加速,有利影响临床终端如实验室确诊感染的发病率和住院时间。化疗剂量强度也增加了患者接受lenograstim,尤其是那些乳房或小细胞肺癌,虽然改善肿瘤反应和生存并没有被证实。Lenograstim还协助在接受骨髓移植的患者中性粒细胞恢复,和刺激生产的自体外周血干细胞(PBSCs)输血后积极的化疗。Lenograstim还动员CD34 +细胞更有效地比白细胞生成素单位剂量而言,已被成功地用于动员PBSCs健康的捐赠者的同种异体移植。随机试验显示增加的疾病缓解lenograstim治疗后患者的急性髓系白血病,没有刺激的恶性爆炸的证据。毒品也显示出潜在的动员良性的PBSCs慢性髓系白血病患者自体。其他研究显示疗效lenograstim患者急性淋巴细胞白血病,再生障碍性贫血,在患有严重慢性嗜中性白血球减少症的儿童和逆转艾滋病患者抗病毒治疗相关的嗜中性白血球减少症,尽管数据并不广泛。进行成本分析lenograstim已经从医院的角度来看,虽然结果不确定。 Cost-effectiveness or cost-benefit data are lacking at present. Lenograstim is well tolerated, with bone pain and injection site reactions being reported most frequently in clinical trials. CONCLUSIONS: Lenograstim has been confirmed as a valuable adjunct to minimise the haematological toxicity of myelosuppressive chemotherapy in patients with malignant disease. The drug also enhances neutrophil recovery in patients undergoing stem cell rescue, and assists PBSC mobilisation. Data indicate clinical benefit with lenograstim in myeloid disorders, with no evidence of malignant blast cell proliferation. Further studies are required to assess more fully the pharmacoeconomic implications of the use of lenograstim and other recombinant growth factors, to provide more data on the efficacy of the drug in the management of disease-related neutropenia, and to clarify fully its position relative to filgrastim.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Lenograstim